What it’s for
- LDL reduction and cardiovascular-risk management
An injectable prescription medicine that inhibits PCSK9 and lowers LDL cholesterol.
Purpose, evidence and practical considerations.
Clinical evidence and approved indications support its use in defined patients. The benefit depends on baseline risk and does not make it a general longevity supplement.
Confidence: strong
Common reactions include injection-site and upper-respiratory symptoms; serious hypersensitivity can occur. Treatment requires diagnosis, lipid monitoring, correct storage and injection technique, and clinician oversight.
Evolocumab binds PCSK9, reducing LDL-receptor degradation and increasing hepatic clearance of LDL cholesterol. It is a biologic injection, not a supplement or generic cholesterol intervention.
Regulatory status: FDA-approved prescription biologic for LDL-C reduction and cardiovascular-risk reduction in labelled populations
The evidence on this page does not automatically apply to:
How people use it, with their schedules, context and original sources.
140 mg · every 2 weeks
PCSK9 inhibitor; apoB / cholesterol
twice monthly injection
genetic cardiovascular risk; targeting apoB of 30–40 mg/dL from a baseline of about 90–100
Dose and schedule patterns reported in public protocols; these are observations, not prescribing advice. Private and hidden usage is excluded.
Brand variants reported in public protocols. Private entries are excluded, and inclusion is not an endorsement.
These share a protocol with this intervention. This does not establish that they work together or are suitable alternatives.